Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...

With sales of Novo Nordisk ... ($6.2 billion) on similar projects. Meanwhile, thanks to the completion of Novo Holdings’ $16.5 billion Catalent acquisition in December, Novo Nordisk has ...

Morgan Stanley (NYSE:MS) initiated coverage on shares of Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO), a global healthcare company specializing in diabetes care and other serious chronic conditions. The ...

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

Sales of type 2 diabetes drug Ozempic jumped in 2024 by over a quarter to DKK120.3billion, as human insulin revenues increased by 15 per cent to DKK55.4billion. Consequently, Novo Nordisk's ...

On the charts, today's pop has NVO on track to snap a three-day losing streak. The stock still hasn't recovered from its ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs. Novo Nordisk said its fourth ...

REDEFINE 2 is evaluating CagriSema in type 2 diabetes patients who are also either obese or overweight. Novo Nordisk’s CEO Lars Fruergaard Jorgensen said the company “remains confident in ...

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its popular diabetes and weight loss medicines, including Wegovy and ...

Novo Nordisk said sales of Wegovy more than doubled to 19.87 billion Danish kroner ($2.76 billion) in the fourth quarter, which was just shy of estimates, while sales of diabetes drug Ozempic rose ...